title: Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
abstract: BACKGROUND
  The high-density lipoprotein (HDL)-associated anti-oxidative and anti-inflammatory enzyme, paraoxonase-I, has been found previously to be lower in type 2 diabetes mellitus. We studied whether statin and fibrate treatment, alone and in combination, affect serum paraoxonase-I activity in conjunction with changes in HDL cholesterol in diabetic patients.
  
  
  METHODS
  A placebo-controlled crossover study was carried out in 14 type 2 diabetic patients to test the effect of 8 weeks of active treatment with simvastatin (40 mg daily), bezafibrate (400 mg daily), and their combination on serum paraoxonase-I activity, measured as its activity towards arylesterase and paraoxon. Serum paraoxonase-I activity was also compared between these diabetic patients and 49 non-diabetic control subjects.
  
  
  RESULTS
  Serum arylesterase activity was lower in type 2 diabetic patients compared to control subjects (P < 0.001), but the difference in paraoxonase activity was not significant (P = 0.22). Neither arylesterase (P = 0.24) nor paraoxonase activity (P = 0.37) was increased in response to treatment, despite higher HDL cholesterol and apolipoprotein A-I during combination therapy (P < 0.05 for both).
  
  
  CONCLUSIONS
  Short-term administration of simvastatin and bezafibrate, even when combined, is ineffective in raising serum paraoxonase-I activity in type 2 diabetes.
authors.affiliation: University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands. r.p.f.dullaart@int.umcg.nl
authors.forename: R P F
authors.initials: RP
authors.lastname: Dullaart
authors.forename: R
authors.initials: R
authors.lastname: de Vries
authors.forename: H A M
authors.initials: HA
authors.lastname: Voorbij
authors.forename: W J
authors.initials: WJ
authors.lastname: Sluiter
authors.forename: A
authors.initials: A
authors.lastname: van Tol
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D043303:Aryldialkylphosphatase / Q000378:metabolism*; D001629:Bezafibrate / Q000008:administration & dosage*; D002265:Carboxylic Ester Hydrolases / Q000378:metabolism; D016022:Case-Control Studies; D008076:Cholesterol, HDL / Q000378:metabolism*; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004338:Drug Combinations; D006801:Humans; D008297:Male; D008875:Middle Aged; D019821:Simvastatin / Q000008:administration & dosage*; D013223:Statistics as Topic
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D004338:Drug Combinations; D019821:Simvastatin; D002265:Carboxylic Ester Hydrolases; C019734:arylesterase; D043303:Aryldialkylphosphatase; D001629:Bezafibrate